Circulating mutant DNA to assess tumor dynamics.
The measurement of circulating nucleic acids has transformed the management of chronic viral infections such as HIV. The development of analogous markers for individuals with cancer could similarly enhance the management of their disease. DNA containing somatic mutations is highly tumor specific and thus, in theory, can provide optimum markers. However, the number of circulating mutant gene fragments is small compared to the number of normal circulating DNA fragments, making it difficult to detect and quantify them with the sensitivity required for meaningful clinical use. In this study, we applied a highly sensitive approach to quantify circulating tumor DNA (ctDNA) in 162 plasma samples from 18 subjects undergoing multimodality therapy for colorectal cancer. We found that ctDNA measurements could be used to reliably monitor tumor dynamics in subjects with cancer who were undergoing surgery or chemotherapy. We suggest that this personalized genetic approach could be generally applied to individuals with other types of cancer.
16 references, click to expand
-
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.N Engl J Med. 2004 Aug 19;351(8):781-91 PMID: 15317891
-
BEAMing up for detection and quantification of rare sequence variants.Nat Methods. 2006 Feb;3(2):95-7 PMID: 16432518
-
BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions.Nat Methods. 2006 Jul;3(7):551-9 PMID: 16791214
-
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance.Mutat Res. 2007 May-Jun;635(2-3):105-117 PMID: 17257890
-
Tumor microenvironment: the role of the tumor stroma in cancer.J Cell Biochem. 2007 Jul 1;101(4):805-15 PMID: 17226777
-
Advanced sequencing technologies: methods and goals.Nat Rev Genet. 2004 May;5(5):335-44 PMID: 15143316
-
The genomic landscapes of human breast and colorectal cancers.Science. 2007 Nov 16;318(5853):1108-13 PMID: 17932254
-
Serial assessment of human tumor burdens in mice by the analysis of circulating DNA.Cancer Res. 2007 Oct 1;67(19):9364-70 PMID: 17909045
-
Detection and quantification of mutations in the plasma of patients with colorectal tumors.Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16368-73 PMID: 16258065
-
Isolation of rare circulating tumour cells in cancer patients by microchip technology.Nature. 2007 Dec 20;450(7173):1235-9 PMID: 18097410
-
Circulating nucleic acids (CNAs) and cancer--a survey.Biochim Biophys Acta. 2007 Jan;1775(1):181-232 PMID: 17137717
-
Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer.Cancer Invest. 2005;23(4):338-51 PMID: 16100946
-
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations.Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8817-22 PMID: 12857956
-
Mutational analysis using oligonucleotide microarrays.J Med Genet. 1999 Oct;36(10):730-6 PMID: 10528850
-
Emerging molecular markers of cancer.Nat Rev Cancer. 2002 Mar;2(3):210-9 PMID: 11990857
-
Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias.Dis Markers. 2005;21(3):105-20 PMID: 16276004
Contact
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
WeChat Official Account
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: product@genelibs.com
Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2
